Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
08:01am, Monday, 24'th Mar 2025
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concie
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
08:31am, Thursday, 20'th Mar 2025
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswi
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
08:31am, Tuesday, 18'th Mar 2025
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnosti
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
07:36am, Thursday, 13'th Mar 2025
Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
09:01am, Monday, 10'th Mar 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
04:45pm, Wednesday, 05'th Mar 2025
NEW YORK , March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAV
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
08:25am, Tuesday, 04'th Mar 2025
NEW YORK , March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAV
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
08:31am, Thursday, 27'th Feb 2025
Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUC
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:31am, Tuesday, 25'th Feb 2025
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
08:31am, Thursday, 20'th Feb 2025
LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis NEW YORK , Feb. 20
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
08:30am, Tuesday, 18'th Feb 2025
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device,
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08:57am, Thursday, 06'th Feb 2025
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
07:56am, Monday, 13'th Jan 2025
Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW YORK , Jan. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"),
Lucid Inks New Partnership With VITALExam: Stock to Gain?
08:25am, Thursday, 26'th Dec 2024
LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters.
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
08:01am, Monday, 23'rd Dec 2024
NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
